Print Email

What We Are Funding

PPMD invests in research that will impact every boy touched by Duchenne, no matter his age, stage of progression, or mutation. Our Funding Portfolio highlights new treatments and therapies at various stages of development. Your support can turn their promise into success.


Current Projects Needing Funding


2014 Predicting the benefit vs the side effects of corticosteroids in Duchenne muscular dystrophy Dr. Robert Griggs, University of Rochester Research Grant $78,357
2013 Preclinical testing of procysteine for reducing dystropathology in the mdx mouse model of Duchenne Muscular Dystrophy Dr. Peter Arthur, University of Western Australia Exploratory Grant $49,998
2013 Early Treatment with Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular Dystrophy- 2 year extension trial Dr. Subha Raman, Cincinnati Children's Hospital Medical Center Investigator Grant $52,500
2013 microRNAs as a modifier of exon skipping efficacy: feasibility of co-delivery Dr. Erica Reeves, Reveragen Exploratory Grant $49,991
2012 Pilot Project to identify genetic modifiers of Duchenne muscular dystrophy Dr. Stanley Nelson, University of California, Los Angeles Research Grant $100,000
2012 Exons 45-55 skipping with a cocktail antisense oligo Dr. Toshifumi Yokota, University of Alberta Research Grant $50,000
2012 Long-term efficacy and side effect profile of compound A, a selective glucocorticoid receptor modulator in mdx mice Dr. Kanneboyina Nagaraju, Children’s Research Institute Research Grant $50,000
2012 Development of MEMRI as an outcome measure for pre-clinical studies in the mdx mouse Dr. Volker Straub, University of Newcastle Upon Tyne Research Grant $49,003
2012 Magnetic Resonance Imaging as a Biomarker in Muscular Dystrophy Supplement Dr. Kristen Vandenborne, University of Florida Research Grant $59,598
2012 Clinically Meaningful Outcomes for Duchenne Muscular Dystrophy Therapeutic Trials Dr. Erik Henricson, University of California, Davis Research Grant $175,000
2012 Early treatment with Aldosterone antagonism attenuates cardiomyopathy in Duchenne MD (Epleronone Trial) Dr. Kan Hor, Cincinnati Children's Hospital Medical Center Research Grant $84,092

Complete Funding Portfolio

In this section

Funding Portfolio
Programs & Priorities
Review Committees 

Facebook YouTube Twitter
Quick Links
PPMD Sites

Shop Amazon, End Duchenne

Action Alert